Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: A naturalistic study

Journal of Developmental and Behavioral Pediatrics

Volumn 29, Issue 2, 2008, Pages 106-116

  Capone, George T ^a,b   Goyal, Parag ^a   Grados, Marco ^b   Smith, Brandon ^c   Kammann, Heather ^a  

^a KENNEDY KRIEGER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Aberrant Behavior Checklist; Autistic spectrum disorder; Disruptive behavior; Down syndrome; Dual diagnosis; Intellectual disability; Risperidone; Self injury; Trisomy 21

Indexed keywords

BUSPIRONE; CETIRIZINE; CHOLINE; DIMETHYLGLYCINE; FLUTICASONE; FLUVOXAMINE; GABAPENTIN; GUANFACINE; METOCLOPRAMIDE; MONTELUKAST; NALTREXONE; NEFAZODONE; OMEPRAZOLE; PIRACETAM; RANITIDINE; RISPERIDONE; SALBUTAMOL; THYROXINE; TRIAMCINOLONE;

ADOLESCENT; AGGRESSION; ARTICLE; AUTISM; AUTOMUTILATION; BEDTIME DOSAGE; CHILD; CHILD BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DISRUPTIVE BEHAVIOR; DOWN SYNDROME; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; HYPERPHAGIA; HYPERSALIVATION; INTELLECTUAL IMPAIRMENT; IRRITABILITY; LETHARGY; LINEAR REGRESSION ANALYSIS; MALE; MORNING DOSAGE; NATURALISTIC INQUIRY; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; RATING SCALE; REGRESSION ANALYSIS; SEDATION; SIDE EFFECT; SLEEP PATTERN; SPEECH DISORDER; STEREOTYPY; TONGUE DISEASE; TREATMENT DURATION; TREMOR; WEIGHT GAIN;

ADOLESCENT; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; AUTISTIC DISORDER; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; COMORBIDITY; DOWN SYNDROME; FEMALE; HUMANS; LINEAR MODELS; MALE; MENTAL RETARDATION; RISPERIDONE; SELF-INJURIOUS BEHAVIOR;

EID: 42149180506     PISSN: 0196206X     EISSN: None     Source Type: Journal    
DOI: 10.1097/DBP.0b013e318165c100     Document Type: Article

References (42)

1. Gath A, Gumley D. Behaviour problems in retarded children with special reference to Down's syndrome. Br J Psychiatry. 1986;149:156-161.
2. Gillberg C, Persson E, Grufman M, et al. Psychiatric disorders in mildly and severely mentally retarded urban children and adolescents: epidemiological aspects. Br J Psychiatry. 1986;149:68-74.
3. Lund J. Psychiatric aspects of Down's syndrome. Acta Psychiatr Scand. 1988;78:369-374.
4. Myers B, Pueschel SM. Psychiatric disorders in persons with Down syndrome. J Nerv Ment Dis. 1991;179:609-613.
5. Ghaziuddin M, Tsai L, Ghaziuddin N. Autism in Down's syndrome: presentation and diagnosis. J Intellect Disabil Res. 1992;36:449-456.
6. Kent L, Evans J, Paul M, et al. Comorbidity of autistic spectrum disorders in children with Down syndrome. Dev Med Child Neurol. 1999;41:153-158.
7. Capone G, Grados M, Kaufmann W, et al. Down Syndrome and comorbid autism-spectrum disorder: characterization using the Aberrant Behavior Checklist. Am J Med Genet. 2005;134A:373-380.
8. McCracken JT, McGough J, Shah B, et al., Research Units on Pediatric Psychopharmacology. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314-321.
9. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114:634-641.
10. McDougle C, Holmes J, Bronson M, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J Am Acad Child Adolesc Psychiatry. 1997;36:685-693.
11. Masi G, Cosenza A, Mucci M, et al. Open trial of risperidone in 24 young children with pervasive developmental disorder. J Am Acad Child Adolesc Psychiatry. 2001;40:1206-1214.
12. Aman M, DeSmedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002;159:1337-1346.
13. Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002;41:1026-1036.
14. Zarcone J, Hellings J, Crandall K, et al. Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. Am J Ment Retard. 2001;106:525-538.
15. Findling R, Aman M, Eerdekens M, et al. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry. 2004;161:677-648.
16. Meltzer H.. The mechanism of action of novel antipsychotic drugs. Schizophr Bull. 1991;17:263-287.
17. Ichikawa J, Ishii H, Bonaccorso S, et al. 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001;76:1521-1531.
18. Campbell M, Armenteros J, Malone R, et al. Neuroleptic related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry. 1997;36:835-843.
19. Krug D, Arick J, Almond P. Behavior checklist for identifying severely handicapped individuals with high levels of autistic behavior. J Child Psychol Psychiatr. 1980;21:221-229.
20. Nordin V, Gillberg C. Autism spectrum disorders in children with physical or mental disability or both. II: Screening aspects. Dev Med Child Neurol. 1996;38:314-324.
21. Bayley N. Bayley Scales of Infant Development. San Antonio, TX: Harcourt Brace; 1993:221.
22. Hoon A, Pulsifer M, Gopalan R, et al. Clinical adaptive test/clinical auditory milestone scale in early cognitive assessment. J Pediatr. 1993;123:S1-S8.
23. Aman M, Singh N, Stewart A, et al. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89:485-491.
24. Aman M, Singh N, Stewart A, et al. Psychometric characteristics of the Aberrant Behavior Checklist. Am J Ment Defic. 1985;89:492-502.
25. Brinkley J, Nations L, Abramson R, et al. Factor analysis of the Aberrant Behavior Checklist in individuals with autism spectrum disorders. J Autism Dev Disord. 2007;37:1949-1959.
26. Yudofsky S, Silver J, Jackson W, et al. The overt aggression scale for the objective rating of verbal and physical aggression. Am J Psychiatry. 1986;143:35-39.
27. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
28. Ivanenko A, McLaughlin V, Gozal D. Sleep in children with psychiatric disorders. Pediatr Clin North Am. 2004;51:51-68.
29. Chervin RD. Conduct problems and symptoms of sleep disorders in children. J Am Acad Child Adolesc Psychiatry. 2003;42:201-208.
30. Rossi A, Mancini F, Stratta P, et al. Risperidone, negative symptoms and cognitive deficits in schizophrenia: an open study. Acta Psychiatr Scand. 1997;95:40-43.
31. Green M, Marshall B, Wirshing W, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry. 1997;154:799-804.
32. Bellack A, Schooler N, Marder S, et al. Do clozapine and risperidone affect social competence and problem solving? Am J Psychiatry. 2004;161:364-367.
33. Lidow MS, Williams GV, Goldman-Rakic PS. The cerebral cortex: a case for common site of action of antipsychotics. Trends Pharmacol Sci. 1998;19:136-140.
34. Vgontzas A, Bixler E, Chrousos G. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev. 2005;9:211-224.
35. Hellings J, Zarcone J, Crandall K, et al. Weight gain in a controlled study of risperidone in children, adolescents, and adults with mental retardation and autism. J Child Adolesc Psychopharmacol. 2001;11:229-238.
36. Lieberman J. Metabolic changes associated with antipsychotic use. J Clin Psychiatry. 2004;6(suppl 2):8-13.
37. Stigler K, Potenza M, Posey D, et al. Weight gain associated with atypical antipsychotic use in children and adolescents. Pediatr Drugs. 2004;6:33-44.
38. McConville B, Sorter B. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychosis. J Clin Psychiatry. 2004;65(suppl 6):20-29.
39. Melville C, Cooper S, McGrother C, et al. Obesity in adults with Down syndrome: a case-control study. J Intellect Disabil Res. 2005;49:125-133.
40. Marcus CL, Keens TG, Bautista DB, et al. Obstructive sleep apnea in children with Down syndrome. Pediatrics. 1991;88:132-139.
41. Levanon A, Tarasiuk A, Tal A. Sleep characteristics in children with Down syndrome. J Pediatr. 1999;134:755-760.
42. Correll C, Carlson H. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45:771-791.